Katya Andresen, Cigna Group’s chief data, digital, and AI officer, is redefining the role of technology in healthcare. Since joining the company in 2021, Andresen has argued that the critical question is not merely how to use AI tools, but how to lead in the age of AI to improve health outcomes.
Financial Impact and Proactive Care
Cigna projects that using AI and predictive analytics to identify chronic conditions—such as cancer and kidney disease—could save an estimated $200 million over the next three years. Additionally, the company announced a $100 million investment through 2028 to reduce the time clinicians spend on documentation and to speed up the prescription process.
The Shift to Biosimilars
One of Cigna’s most successful AI applications involves promoting biosimilars, which are lower-cost alternatives to biologic drugs. By analyzing thousands of customer conversations, Cigna used AI insights to craft targeted digital messaging. This campaign led more than 80% of patients to opt for the biosimilar alternative, saving patients hundreds of millions of dollars while increasing the company’s margins.
Operational Efficiency and Governance
In clinical settings, AI-enabled summarization has reduced note-taking time by up to 90% for health practitioners at Cigna’s MDLIVE service. Meanwhile, Andresen emphasizes that as a highly regulated organization, Cigna already possesses robust data governance controls, facilitating the safe adoption of generative AI.
- $200M projected savings via predictive analytics for chronic conditions.
- $100M investment to reduce clinician administrative burden by 2028.
- 80% adoption rate of cheaper biosimilars driven by AI-targeted messaging.
- 90% reduction in note-taking time for MDLIVE clinicians.
